TY - JOUR T1 - Protecting the kidney from complement: atypical haemolytic uraemic syndrome JF - Clinical Medicine JO - Clin Med SP - s89 LP - s94 DO - 10.7861/clinmedicine.14-6-s89 VL - 14 IS - Suppl 6 AU - Vicky Brocklebank AU - David Kavanagh Y1 - 2014/12/01 UR - http://www.rcpjournals.org/content/14/Suppl_6/s89.abstract N2 - Atypical haemolytic uraemic syndrome is a thrombotic microangiopathy with a predominant renal phenotype. Research developments in the last 15 years have led to the elucidation of the role of complement over activation in the pathogenesis of the disease. This was to lead to the successful introduction of targeted pharmacological therapy, in the form of the complement inhibitor, eculizumab. ER -